Welcome to our dedicated page for HARVARD BIOSCIENCE SEC filings (Ticker: HBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harvard Bioscience filings document regulatory disclosures for a life science research tools company with Cellular and Molecular Technologies and Preclinical product families. Form 8-K reports cover operating results, preliminary financial information, corporate presentations, restructuring and manufacturing consolidation actions, executive employment agreements, and stockholder votes affecting the company’s common stock.
Proxy statements describe board matters, executive compensation, pay-versus-performance data, equity awards, charter amendments and special-meeting proposals, including reverse stock split authority and related voting results. The filings also frame governance, capital-structure and forward-looking disclosure topics tied to the company’s global sales channels and manufacturing footprint.
Harvard Bioscience reported first-quarter 2026 revenue of $20.8 million, down about 5% from the prior year as academic and Asia-Pacific demand softened. Gross profit held steady at $12.2 million, with gross margin improving to 59.0% from 56.0% on a more favorable product mix.
The company posted a net loss of $3.4 million, far smaller than the prior-year loss that was dominated by a large goodwill impairment. Operating expenses declined sharply without that charge, but interest expense nearly doubled to $1.7 million following the high-rate 2025 loan refinancing.
Cash and cash equivalents were $7.1 million against $40 million of term debt, and the company remained in compliance with liquidity and adjusted EBITDA covenants. Management states prior going concern doubts have been alleviated. A 1-for-10 reverse stock split was completed to support Nasdaq listing compliance, and the new Project Viking manufacturing consolidation is expected to deliver several million dollars of annual cost savings after 2027, with restructuring charges incurred beginning in this quarter.
Harvard Bioscience, Inc. furnished an investor presentation outlining its strategy, recent refinancing and financial outlook. The company reported FY25 revenue of $87M with 54% recurring revenue and $8M adjusted EBITDA, and is guiding FY26 revenue growth of 2–4%, adjusted EBITDA growth of 6–10%, and an adjusted gross margin of 58–60%. A debt refinancing extends maturity to December 2029, adds a $7M convertible Term C loan at $10.00/share with automatic conversion above $15.00, and is expected to reduce annual debt service by $3M. The company plans to close its Holliston, MA plant under “Project Viking,” consolidating manufacturing and targeting $3M of adjusted EBITDA improvement in 2027 and $4M from 2028 onward.
Harvard Bioscience reported mixed first-quarter 2026 results. Revenue was $20.8 million versus $21.8 million a year earlier, while gross margin improved to 59% from 56% as the company shifted toward higher-margin products such as organoid platforms and BTX Electroporation and SoHo Telemetry systems.
Net loss narrowed sharply to $3.4 million from $50.3 million, which previously included a $48.0 million goodwill impairment. Adjusted EBITDA was $0.8 million, unchanged from last year, and adjusted EBITDA margin held at 3.7%. Operating cash flow moved from $3.0 million provided to $0.7 million used, largely due to one-time costs tied to debt refinancing.
Management said first-quarter revenue was in line with expectations, reaffirmed full-year 2026 guidance, and projected mid–single-digit revenue growth, margin expansion, and continued adjusted EBITDA profitability in the second quarter as new product adoption scales.
Harvard Bioscience, Inc. is asking stockholders to vote at a virtual 2026 annual meeting on June 2, 2026. Holders of 4,510,217 shares of common stock as of April 7, 2026 may participate and vote online.
Stockholders will elect two Class II directors (John Duke and Katherine A. Eade), ratify Grant Thornton LLP as auditor for 2026, cast an advisory vote on executive pay, and consider amendments to increase the Employee Stock Purchase Plan by 120,000 shares and the 2021 Incentive Plan by 400,000 shares of common stock. The board recommends voting FOR all proposals and highlights its independent committee structure, ESG initiatives, clawback and insider trading policies, and detailed director and executive compensation programs.
Harvard Bioscience Chief Financial Officer Mark T. Frost reported an equity compensation grant rather than a market trade. He acquired 30,000 restricted stock units (RSUs) at no cost, which will vest in three equal installments on March 20, 2027, 2028, and 2029, subject to his award agreement. After this grant, he is shown with 47,500 common stock equivalents, including 5,000 shares purchased on March 16, 2026, 10,000 additional RSUs scheduled to vest on May 12, 2026, and 2,500 shares of common stock beneficially owned. The filing also notes that these RSU and share counts were adjusted to reflect a 10-for-1 reverse stock split that took effect on March 13, 2026.
Harvard Bioscience Chief Financial Officer Mark T. Frost bought 5,000 shares of common stock in an open-market purchase at $5.00 per share. Following this transaction, he directly owns a total of 17,500 shares, including 10,000 restricted stock units scheduled to vest on May 12, 2026.
Duke John D reported acquisition or exercise transactions in this Form 4 filing.
HARVARD BIOSCIENCE INC reported that Chief Executive Officer and director John D. Duke received a grant of 75,000 shares of Common Stock on 2026-03-20. The award was reported at a price of $0.0000 per share, indicating a compensation-related grant rather than a market purchase. Following this transaction, his directly owned Common Stock holdings increased to 180,000 shares.
BroadOak Income Fund, BroadOak Fund VI, BroadOak Capital Partners, and William Snider report significant ownership in Harvard Bioscience common stock. Mr. Snider is deemed to beneficially own 846,000 shares, or 15.97% of the company, based on 4,471,989 shares outstanding as of March 5, 2026, including shares underlying warrants and a convertible loan.
The position arises from a senior secured Loan and Security Agreement under which Harvard Bioscience obtained three term loans of $10.0 million, $22.5 million, and $7.5 million. The Term C Loan is convertible into common stock at $10.00 per share and can automatically convert if the share price exceeds $15.00 for thirty consecutive trading days. Lenders also received seven‑year warrants for 200,000 shares at a $5.00 exercise price and an effective resale registration statement.
The loans bear interest at not less than 12.80% per year initially, include prepayment premiums and a 10.00% exit fee on repaid amounts, and are secured by substantially all assets of Harvard Bioscience and its guarantor subsidiaries. Proceeds are used to refinance the prior credit facility, pay transaction costs, and support working capital and general corporate purposes. BroadOak, through the administrative agent, obtained the right to nominate one director; Mr. Snider has been appointed to the board and its compensation committee and may receive director compensation and equity awards. He also purchased 21,000 shares in open‑market transactions in March 2026 with personal funds.
Harvard Bioscience director Stephen J. Denelsky bought 10,000 shares of common stock in an open-market transaction at $4.87 per share. After this purchase on March 17, 2026, he directly holds 21,000 shares, including 11,000 restricted stock units scheduled to fully vest on September 5, 2026.
The footnotes also note that on March 13, 2026, Harvard Bioscience completed a 10-for-1 reverse stock split, and the 11,000 restricted stock units were adjusted from a previously reported 110,000 units to reflect this split.
Harvard Bioscience director William Snider reported open-market purchases of company stock. On March 16, 2026, he bought 12,525 shares of common stock at a weighted average price of $4.99 per share, with actual trade prices ranging from $4.80 to $4.95. On March 17, 2026, he bought an additional 8,475 shares at a weighted average price of $4.85, with individual trades between $4.85 and $5.00. Following these transactions, he directly holds 32,000 shares of common stock, plus 11,000 restricted stock units that fully vest on December 17, 2026. The filing notes a 10-for-1 reverse stock split of Harvard Bioscience common stock on March 13, 2026, which reduced the previously reported 110,000 restricted stock units to 11,000.